Alnylam Develops Blood-Based RNAi Monitoring Approach
February 09, 2012
Alnylam Develops Blood-Based RNAi Monitoring Approach
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam Releases Proof-of-concept Data on Preclinical Porphyria Drug
May 21, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Novartis, Tekmira, and More
May 21, 2013 / Gene Silencing News - Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13
May 16, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Merck, BASF, and More
April 18, 2013 / Gene Silencing News - Tekmira to Present Cancer Drug Data at AACR, Aims for Phase II by Year-End
March 28, 2013 / Gene Silencing News